久久国产中文娱乐网_日韓一級高清_a级毛片黄免费观看m_宝贝对着摄像头自己做忘羡_亚洲黄色天堂网_高清有码巨乳日本在线_俄罗斯6一12呦女精品不卡_欧美日批在线观看视频_最近中文字幕更新免費_粉嫩虎白女P虎白女在线

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. The abstracts highlight updates regarding Eisai’s in-house discovered LENVIMA??(lenvatinib mesylate, the orally available kinase inhibitor, “lenvatinib”), and Halaven??(eribulin mesylate, “eribulin”, halichondrin class microtubule dynamics inhibitor).

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alzheimer’s disease/dementia will be presented at World Sleep Congress (World Sleep 2019), from September 20 to 25 in Vancouver, Canada.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai’s sixth selection.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test – Cogstate Brief Battery (CBB) – developed by Cogstate Ltd. (Headquarters: Australia, “Cogstate”), in Japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods).

On August 7, 2019, Eisai China Inc. was invited to participate in a CPC sub-branch co-construction campaign in Zhenping organized and arranged by the School of Pharmacy of China Pharmaceutical University.? Seventeen people, including Shiying Zhang, Party Secretary of School of Pharmacy, Yan Huang, Deputy Party Secretary and other relevant leaders from China Pharmaceutical University, Ningbang Wang, Deputy Director of Jiangning High-tech Park Administrative Committee, Wei Guo, Chief Physician and Director of the Geriatric Endocrinology Department of Shaanxi Provincial People’s Hospital, Wei Cui, Chief Physician and? Director of? Department of Geriatric Endocrinology of First Affiliated Hospital of Xi’an Jiaotong University, Xiaojing Zhang, Director of the General Practice Department and Emergency Treatment Department of Second Affiliated Hospital of Xi’an Jiaotong University, as well as Xiongwei Gu Party Branch Secretary and head of Internal Audit Department of Eisai China Inc., came to Zhenping.? The co-construction campaign at this time mainly included: the drug donation by Eisai China Inc., experts’ free clinic services, “rational drug use” lectures, hierarchical diagnosis and treatment, transfer treatment, academic exchanges, etc.